FOXO4-DRI · DOSSIER

FOXO4-DRI

FOXO4-DRI · FOXO4 D-Retro-Inverso-Peptid
LEGAL DE · NOT APPROVEDEVIDENCE · PRECLINICAL2 STUDIES
FIG.01 — SIGNAL CHAIN
02

Mechanism of action

What FOXO4-DRI does in the body — step by step.

01

FOXO4-DRI is a synthetic D-retro-inverso peptide (mirror-image design for higher stability) that disrupts the interaction between the transcription factor FOXO4 and the tumour suppressor p53.

02

In senescent ("aged") cells this interaction retains p53 in the nucleus and prevents their self-destruction.

03

By disrupting it, p53 is intended to be released and selectively trigger apoptosis of senescent cells (a senolytic approach).

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
FOXO4-DRI has so far been studied exclusively preclinically.
FOXO4-DRI has so far been studied exclusively preclinically.
A widely noted study (2017) described the selective elimination of senescent cells in animal models; more recent studies investigate applications such as keloid fibroblasts or age-related testosterone insufficiency in animal models.
Controlled human studies do not exist.
Safety and efficacy in humans are not demonstrated.
04

Known risks

Without human data, safety statements are limited. What is known:

01
No human studies — safety profile entirely unknown
02
Interference with p53/apoptosis signalling with potentially far-reaching consequences
03
Long-term and off-target effects unknown
04
Product quality cannot be verified from unapproved sources
05

Cited studies

Chronological — links lead to the source.

2020
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells
PubMed 31959736 →
2025
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of p53
PubMed 39994346 →
06

Frequently asked questions

What is FOXO4-DRI?+

FOXO4-DRI is a synthetic D-retro-inverso peptide (mirror-image design for higher stability) that disrupts the interaction between the transcription factor FOXO4 and the tumour suppressor p53.

What type of peptide is FOXO4-DRI?+

FOXO4-DRI belongs to the Other class.

What is FOXO4-DRI used for?+

In research, FOXO4-DRI has primarily been investigated in the context of: Anti-aging. These are research findings (evidence: preclinical), not proven benefits in humans and not a usage recommendation.

Is FOXO4-DRI legal in Germany?+

FOXO4-DRI is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Is FOXO4-DRI FDA-approved / legal in the US?+

No. FOXO4-DRI is not FDA-approved as a drug in the US; it is mostly sold as a research chemical and not for human consumption.

Is FOXO4-DRI legal in Canada?+

No. FOXO4-DRI is not authorized by Health Canada and not intended for human consumption.

Where can I buy FOXO4-DRI?+

Peptica sells nothing and names no sources. FOXO4-DRI is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of FOXO4-DRI?+

Peptica publishes no dosing. There are no approved dosing guidelines for FOXO4-DRI; figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.

Is FOXO4-DRI banned in sport (WADA)?+

FOXO4-DRI is currently not on the WADA Prohibited List.

What are the known risks of FOXO4-DRI?+

Documented risks include: No human studies — safety profile entirely unknown; Interference with p53/apoptosis signalling with potentially far-reaching consequences. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is FOXO4-DRI?+

The evidence is classified as “preclinical”. 2 studies are cited on this page.

Which peptides are related to FOXO4-DRI?+

Closely related entries: Epithalon. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanynot approved

FOXO4-DRI is not approved as a medicine and is solely an experimental research substance. Not on the WADA Prohibited List. Interfering with p53 signalling is potentially risky; obtaining it as a research chemical is highly risky.

Legal status varies by country and can change. This is not legal advice.

SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01